In addition, our MUC1-Vax-DC vaccine has some potential clinical applications and challenges; therefore, it is of great significance to test whether this novel human MUC1-Vax-DC vaccine can induce anti-PD-L1 antibody and CTL reaction in cancer patients, and to test the safety of this vaccine. Here, MUC1 is linked to cancer.